<DOC>
	<DOC>NCT02080767</DOC>
	<brief_summary>The purpose of this clinical protocol is to treat individuals with Tecovirimat after exposure to orthopox viruses.</brief_summary>
	<brief_title>Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure</brief_title>
	<detailed_description />
	<mesh_term>Smallpox</mesh_term>
	<mesh_term>Monkeypox</mesh_term>
	<criteria>DoDaffiliated personnel (including US civilian employees, contractors and other US personnel and dependents, as well as allied military forces and local nationals) of any age, not breastfeeding Has been exposed to or infected with orthopox viruses (ie, variola (smallpox), vaccinia, monkeypox, or cowpox) OR Has developed serious complications from vaccinia vaccination (eg, eczema vaccinatum, progressive vaccinia, generalized vaccinia that is severe or persistent, and select cases of inadvertent inoculation due to severe pain related to mucosal involvement, ocular involvement) resulting from vaccination, secondary transmission, or other exposure Is available for clinical followup for duration of the treatment and followup period Must be able to swallow capsules Has hypersensitivity to tecovirimat Unable or unwilling to cooperate with the requirements of the treatment protocol Breastfeeding patients. Note that breastfeeding females will be counseled that tecovirimat has not been studied in breastfeeding women and may opt to cease breastfeeding for the duration of the treatment and at least 30 days after the last dose of drug and thus be eligible for enrollment. Women who choose to continue breastfeeding will not be enrolled in this treatment protocol.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>